Last reviewed · How we verify
DA-6034 5%
DA-6034 is a topical ophthalmic agent that reduces intraocular pressure and promotes aqueous humor outflow.
DA-6034 is a topical ophthalmic agent that reduces intraocular pressure and promotes aqueous humor outflow. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | DA-6034 5% |
|---|---|
| Also known as | DA-6034 High dose |
| Sponsor | Dong-A ST Co., Ltd. |
| Drug class | Prostamide analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
DA-6034 is a prostamide analog designed for glaucoma and ocular hypertension treatment. It works by enhancing uveoscleral outflow of aqueous humor through prostaglandin F receptor agonism, thereby lowering intraocular pressure. The 5% formulation represents a topical ophthalmic solution for direct ocular administration.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Iris pigmentation changes
- Eyelash growth
- Eye irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-6034 5% CI brief — competitive landscape report
- DA-6034 5% updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI